article
Why there is a blockage in the biosample system
Dr Robert Hewitt explores why a shift is required in the way that biosamples are sourced by the drug discovery industry, including smaller biotech companies.
List view / Grid view
Dr Robert Hewitt (Biosample Hub)
article
Why the system for biospecimen procurement is broken
Dr Robert Hewitt explains why the need of biospecimen brokers to protect their commercially-sensitive information can result in significant issues for industry end-users and the results of their research.